Ambu A/S
Research Ambu A/S (AMBU-B) on Bullrun: valuation model: 1.2% undervalued, market cap DKK 17.89B, P/E 38.2, dividend yield 0.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAMBU-B
- ExchangeCO
- CountryDenmark
- SectorHealthcare
- IndustryMedical Devices
- CurrencyDKK
- Valuation signal1.2% undervalued
- Market capDKK 17.89B
- P/E38.2
- Dividend yield0.6%
- Financial periodQ2 2026
- RevenueDKK 1.57B
- Net incomeDKK 121.00M
- Gross margin60.3%
Valuation Snapshot
Bullrun's latest valuation model marks Ambu A/S as 1.2% undervalued; latest market cap is DKK 17.89B; P/E is 38.2; dividend yield is 0.6%.
Peer valuation comparison
Latest P/E is 38.21x versus a Healthcare sector median of 24.46x (56.2% above).
Latest dividend yield is 0.58% versus a Healthcare sector median of 2.11% (72.5% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | DKK 6.13B | DKK 552.00M | n/a | 59.8% | n/a | DKK 691.00M | DKK 5.00M | DKK 6.10B |
| FY2024 | DKK 6.04B | DKK 609.00M | DKK 674.00M | 60.2% | 2.28 | DKK 640.00M | DKK 0 | DKK 5.91B |
| FY2023 | DKK 5.39B | DKK 235.00M | DKK 725.00M | 59.4% | 0.88 | DKK 157.00M | DKK 160.00M | DKK 5.39B |
| FY2022 | DKK 4.78B | DKK 168.00M | DKK 447.00M | 56.8% | 0.64 | DKK 187.00M | DKK 340.00M | DKK 4.26B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | DKK 17.89B | 38.2 | 0.5% | 0.41 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.41 DKK, yield 0.6%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.41 DKK |
| FY2024 | 0.38 DKK |
About Ambu A/S
Ambu A/S, together with its subsidiaries, researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally. The company offers endoscopy products, including bronchoscopes, video laryngoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, ureteroscopes, and displaying and processing units; neurology products, such as EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Ambu A/S overvalued or undervalued?
Bullrun's valuation model currently marks Ambu A/S as 1.2% undervalued.
What is Ambu A/S's market cap?
Ambu A/S's market capitalization is DKK 17.89B.
What is Ambu A/S's P/E ratio?
Ambu A/S's price-to-earnings (P/E) ratio is 38.2.
Does Ambu A/S pay a dividend?
Ambu A/S has a dividend yield of 0.6%.
What does Ambu A/S do?
Ambu A/S, together with its subsidiaries, researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally. The company offers endoscopy products, including bronchoscopes, video laryngoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, ureteroscopes, and displaying and processing units; neurology products, such as EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products; and cardiology products comprising ECG electrodes.